Today we’re excited to announce the addition of two new partners for the International Alliance for Cancer Early Detection (ACED) as it moves into its next phase.
The £50m partnership between Cancer Research UK, University of Manchester, University College London, Knight Cancer Institute at OHSU and University of Cambridge will be joined by the Dana-Farber Cancer Institute and the German Cancer Research Centre.
“The next phase of the expanding ACED network is an exciting opportunity for collaborations in early cancer detection,” said Professor Rebecca Fitzgerald, incoming Chair of the Alliance.
“I am especially excited to be leading a new theme on interception – as a community we recognise that intervening to stop cancer in its track is an essential part of our mission to reduce late-stage cancer.”
Making strides in early detection
Since 2019, ACED has established an extensive research portfolio encompassing biology, technology, and trials, with highlights including the BCAN-RAY study to improve risk assessment of breast cancer in young women, and the bespoke ACED Training Programme to support the next generation of early detection researchers.
“Early detection plays a crucial role in reducing cancer mortality, but meaningful progress requires collaboration across disciplines and institutions,” said Professor Tim Rebbeck, Professor of Cancer Prevention and Member Centre Director at the Dana Farber Cancer Institute.
“The Alliance for Cancer Early Detection is driving this effort by bringing together leading experts to advance cutting-edge research and innovation. Through this collaborative approach, ACED aims to accelerate scientific breakthroughs, improve public health, and lessen the impact of cancer for people everywhere.”
Credit: Amy Warnock